Index S&P 500
P/E -
EPS (ttm) -8.06
Insider Own 8.54%
Shs Outstand 391.00M
Perf Week -10.09%
Market Cap 17.50B
Forward P/E -
EPS next Y -6.72
Insider Trans -0.07%
Shs Float 357.38M
Perf Month 43.53%
Enterprise Value 13.73B
PEG -
EPS next Q -2.58
Inst Own 69.70%
Short Float 19.66%
Perf Quarter 67.98%
Income -3.12B
P/S 7.84
EPS this Y 14.80%
Inst Trans -3.70%
Short Ratio 5.66
Perf Half Y 37.12%
Sales 2.23B
P/B 1.88
EPS next Y 14.95%
ROA -22.31%
Short Interest 70.27M
Perf YTD 51.86%
Book/sh 23.86
P/C 3.88
EPS next 5Y 20.17%
ROE -29.32%
52W High 55.20 -18.87%
Perf Year 7.52%
Cash/sh 11.53
P/FCF -
EPS past 3/5Y - -42.94%
ROIC -31.11%
52W Low 22.28 101.00%
Perf 3Y -77.26%
Dividend Est. -
EV/EBITDA -
Sales past 3/5Y -43.99% 121.86%
Gross Margin 38.93%
Volatility 10.63% 7.24%
Perf 5Y -66.32%
Dividend TTM -
EV/Sales 6.15
EPS Y/Y TTM -38.95%
Oper. Margin -155.15%
ATR (14) 3.09
Perf 10Y -
Dividend Ex-Date -
Quick Ratio 3.73
Sales Y/Y TTM -56.00%
Profit Margin -139.61%
RSI (14) 62.22
Recom 3.00
Dividend Gr. 3/5Y - -
Current Ratio 3.93
EPS Q/Q -1673.01%
SMA20 13.45%
Beta 1.35
Target Price 37.32
Payout -
Debt/Eq 0.08
Sales Q/Q -45.44%
SMA50 38.02%
Rel Volume 0.69
Prev Close 45.45
Employees 5800
LT Debt/Eq 0.07
Earnings Nov 06 BMO
SMA200 57.71%
Avg Volume 12.41M
Price 44.78
IPO Dec 07, 2018
Option/Short Yes / Yes
EPS/Sales Surpr. 72.79% 10.33%
Trades
Volume 7,561,916
Change -1.47%
Date
Action
Analyst
Rating Change
Price Target Change
Today Resumed
Barclays
Equal Weight
$25
Jan-07-26 Resumed
UBS
Neutral
$34
Dec-12-25 Initiated
Jefferies
Hold
$30
Mar-13-25 Initiated
Citigroup
Neutral
$40
Feb-18-25 Downgrade
Barclays
Overweight → Equal Weight
$111 → $45
Jan-29-25 Downgrade
Goldman
Buy → Neutral
$99 → $51
Dec-18-24 Downgrade
Argus
Buy → Hold
Dec-10-24 Resumed
BofA Securities
Underperform
$41
Nov-19-24 Initiated
Berenberg
Hold
$42
Nov-18-24 Upgrade
HSBC Securities
Hold → Buy
$58
Nov-15-24 Initiated
Wolfe Research
Underperform
$40
Oct-17-24 Initiated
Bernstein
Mkt Perform
$55
Sep-13-24 Downgrade
Oppenheimer
Outperform → Perform
Sep-13-24 Downgrade
JP Morgan
Neutral → Underweight
$88 → $70
Sep-13-24 Downgrade
Jefferies
Buy → Hold
$120 → $65
Aug-28-24 Upgrade
HSBC Securities
Reduce → Hold
$82
Aug-07-24 Upgrade
Deutsche Bank
Sell → Hold
$85 → $80
Aug-05-24 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$125 → $90
Feb-26-24 Downgrade
HSBC Securities
Hold → Reduce
$75 → $86
Jan-02-24 Upgrade
Oppenheimer
Perform → Outperform
$142
Show Previous Ratings
Today 11:24AM
Jan-27-26 10:50AM
08:55AM
Jan-26-26 05:50PM
11:15AM
07:00AM
Loading…
07:00AM
Jan-25-26 09:01AM
Jan-24-26 07:00AM
Jan-23-26 01:55PM
11:10AM
(Investor's Business Daily)
Jan-22-26 05:53PM
05:02PM
04:09PM
02:31PM
02:08PM
12:27PM
Loading…
12:27PM
11:39AM
10:51AM
09:31AM
08:08AM
06:27AM
06:22AM
06:17AM
05:19AM
03:38AM
(The Wall Street Journal)
01:03AM
12:01AM
Jan-21-26 08:23PM
07:32PM
07:11PM
04:46PM
Loading…
04:46PM
(The Wall Street Journal)
03:57PM
02:24PM
01:57PM
12:21PM
10:06AM
05:38AM
Jan-20-26 06:00PM
04:21PM
03:31PM
10:24AM
06:58AM
(The Wall Street Journal)
06:00AM
Jan-18-26 11:35PM
08:31AM
Jan-17-26 04:30AM
Jan-16-26 12:45PM
08:55AM
08:06AM
07:07AM
03:56AM
Jan-15-26 08:53AM
08:26AM
Jan-14-26 05:50PM
07:09AM
04:04AM
Jan-13-26 08:21PM
06:18PM
04:43PM
04:35PM
04:30PM
(Investor's Business Daily)
04:27PM
02:57PM
02:24PM
(Investor's Business Daily)
01:26PM
01:04PM
Jan-12-26 05:14PM
11:27AM
10:24AM
08:51AM
07:00AM
Jan-08-26 05:50PM
Jan-07-26 09:26AM
08:55AM
08:04AM
04:35AM
03:58AM
Jan-06-26 11:12AM
Jan-05-26 06:44AM
Dec-30-25 05:45PM
Dec-27-25 10:30AM
Dec-26-25 02:14PM
01:53PM
(Investor's Business Daily)
12:12PM
10:25AM
10:25AM
Dec-23-25 05:45PM
Dec-22-25 08:55AM
Dec-19-25 03:16PM
10:10AM
04:30AM
Dec-18-25 01:14PM
12:32PM
11:51AM
09:54AM
07:00AM
Dec-17-25 01:01PM
07:00AM
Dec-16-25 09:55AM
03:03AM
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
AFEYAN NOUBAR Director Dec 11 '25 Option Exercise 10.90 23,853 259,998 27,777 Dec 15 09:00 AM AFEYAN NOUBAR Director Dec 11 '25 Sale 29.48 23,853 703,306 3,924 Dec 15 09:00 AM Bancel Stephane Chief Executive Officer Dec 11 '25 Option Exercise 10.90 688,073 7,499,996 6,181,970 Dec 15 08:59 AM Flagship Pioneering Inc. Affiliate Dec 11 '25 Proposed Sale 29.49 23,853 703,306 Dec 11 04:30 PM Hussain Abbas Director Dec 09 '25 Sale 27.60 504 13,910 1,515 Dec 11 04:16 PM Hussain Abbas Director Dec 09 '25 Proposed Sale 27.60 504 13,910 Dec 09 10:26 AM Hussain Abbas Director Jun 11 '25 Sale 28.00 312 8,736 580 Jun 12 04:22 PM Hussain Abbas Director Jun 11 '25 Proposed Sale 28.00 312 8,736 Jun 11 10:06 AM Bancel Stephane Chief Executive Officer Mar 03 '25 Buy 31.22 160,314 5,004,318 9,210,686 Mar 04 04:27 PM SAGAN PAUL Director Mar 03 '25 Buy 31.76 31,620 1,004,251 312,027 Mar 04 04:24 PM